ADARx Pharmaceuticals (ADRX) files S-1 for Nasdaq IPO with five-bank syndicate
As seen on the 24/7 Wall St. homepage on September 4, 2026.
ADARx registers for a Nasdaq IPO behind a five-bank syndicate
ADARx Pharmaceuticals filed its S-1 to list on Nasdaq, with J.P. Morgan, Morgan Stanley, TD Cowen, UBS and LifeSci Capital running the books. Terms and deal size are still blank, so the price range in the next amendment is the first real read on demand.
Continue ReadingShow less
ADARx Pharmaceuticals has submitted its S-1 registration statement to the SEC, formally kicking off its path to a public listing on Nasdaq. The first amended S-1 with a price range will be the earliest concrete signal of how underwriters are reading institutional demand.
J.P. Morgan, Morgan Stanley, TD Cowen, UBS, and LifeSci Capital are joint bookrunners on the deal. That syndicate, anchored by two bulge-bracket names and a specialist life-sciences firm, suggests the company is targeting both generalist and sector-focused funds.
Sponsored
_________________________________
What's Your Number...?
Here's a question most people 5y from retirement can't answer: at your current savings rate, how much do you need, and how long will it actually last? A good advisor can put a date on that in a single meeting. SmartAsset's free quiz matches you with up to three fiduciary advisors serving your area, so you can get YOUR retirement number now (sponsor)
__________________________________________
No share count, deal size, or price range has been disclosed in this initial filing, which is standard for a first S-1 but leaves investors without a valuation anchor. The amendment that fills in those terms is the document to track.
ADARx filed on September 4, 2026. Until pricing terms appear in a subsequent amendment, the SEC filing itself is the primary public record available on the company's structure, pipeline, financials, and risk factors.